Founded in 2002
by experienced industry executives, Proreo
Pharma is a privately owned Swiss based
specialty pharmaceutical company.
Proreo
Pharma focuses on the acquisition, development,
and commercialization of innovative specialist
medicines.
In Switzerland and Germany,
the company uses its own commercial
infrastructure to market its products. Further
presence and reach is achieved via a network of
distribution partners.
In the United
Kingdom, Proreo Pharma has set up two companies:
Prospera Pharma Ltd, a joint venture with
Nespera Ltd (Israel/Cyprus), and Ygraine
Therapeutics Ltd. Prospera Pharma is
dedicated to the development of several novel
products in the field of pulmonary hypertension
and cognitive, muscular and endocrine disorders.
Ygraine Therapeutics is developing a new
treatment for aura migraine.
|
NEWS
1 June 2012
Proreo Pharma sets up Ygraine Therapeutics Ltd
press release
3 September 2009
Proreo Pharma sets up German business operation
press release
18 December 2008
Proreo Pharma and Nespera set up joint venture company
Prospera Pharma
press release
7 Febuary 2007
Speciality European
Pharma Ltd acquires Proreo Pharma International
AG
press release
|
